鶹ýӰ

FDA Panel to Weigh In on MDMA Approval; Parents Lost to Overdose; New APA President

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

An FDA will weigh in on Lykos Therapeutics' new drug application for midomafetamine (MDMA) capsules for treating post-traumatic stress disorder (PTSD).

All investigational doses of TEV-'749 -- a once-monthly injection of the atypical antipsychotic olanzapine -- significantly meeting the primary endpoint of the phase III SOLARIS trial, Teva Pharmaceuticals and Medincell announced.

Twelve of 22 patients with post-traumatic stress disorder PTSD treated with investigational COMP360 psilocybin at week 12 in an open-label phase II study, said developer Compass Pathways.

for teens may be backfiring, a psychologist suggested. (New York Times)

More than 321,000 U.S. children from 2011 to 2021. (JAMA Psychiatry)

In California, lawmakers are considering a and other psychedelic drugs to treat mental health conditions. (KFF Health News)

The in August to discuss the best approach to developing drugs for schizophrenia's negative symptoms.

Pediatric emergency department stays were shorter and rates of were lower when children with mental health emergencies received care in a separate observation unit. (JAMA Pediatrics)

Ramaswamy Viswanathan, MD, DrMedSc, of the State University of New York (SUNY) Downstate Health Sciences University, started his term as .

The University of Washington in Seattle opened a new 150-bed , aimed at managing hard-to-treat patients. (Seattle Times)

Customers of the will receive notices soon about refunds stemming from a 2023 privacy settlement with the Federal Trade Commission.

About 25% of people 16 or older with insulin-dependent diabetes had , a meta-analysis of 45 studies showed. (Eating Behaviors)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.